8-K: Connect Biopharma Q3 2025: Rademikibart Progress, Rising Losses

Connect Biopharma reported increased net losses in Q3 2025 despite progress in its rademikibart clinical trials and regulatory acceptance in China.

Summary

• Reported financial results for the three and nine months ended September 30, 2025.
• Recruitment is ongoing for Phase 2 Seabreeze STAT studies of rademikibart for acute exacerbations in asthma and COPD.
• Topline data from both Seabreeze STAT studies is expected in the first half of 2026.
• Simcere, the exclusive licensee in Greater China, had its New Drug Application (NDA) for rademikibart for atopic dermatitis accepted by China's NMPA in July 2025.
• The company completed the termination of its American Depositary Receipt (ADR) program and directly listed ordinary shares on Nasdaq.
• Cash, cash equivalents, and short-term investments were $54.8 million as of September 30, 2025, with an expected cash runway into 2027.
• Net loss for Q3 2025 was $17.2 million ($0.31 per share), compared to $12.9 million ($0.23 per share) for Q3 2024.
• Net loss for the nine months ended September 30, 2025, was $40.4 million ($0.73 per share), compared to $6.7 million ($0.12 per share) for the same period in 2024.

Sentiment

Score: 5

Explanation: While the company achieved significant clinical and regulatory milestones, particularly the NDA acceptance in China for rademikibart and positive Phase 2 asthma data, its financial performance showed a substantial increase in net loss and a sharp decline in collaboration revenue. The cash runway into 2027 provides stability, but the increased burn rate and reduced revenue are concerning.

Positives

• New Drug Application (NDA) for rademikibart for atopic dermatitis was accepted by China's NMPA in July 2025, a significant regulatory milestone.
• Eligible to receive up to $110 million in remaining milestone payments and low double-digit tiered royalties on net sales from Simcere's license agreement in Greater China.
• The atopic dermatitis market in China represents a considerable opportunity, with an estimated 70 million patients.
• Presented positive data at ERS 2025 from the global Phase 2 trial of rademikibart in moderate-to-severe uncontrolled asthma, showing rapid and significant improvement in lung function and asthma control.
• Cash, cash equivalents, and short-term investments of $54.8 million are expected to fund operations into 2027.
• Completed the termination of the ADR program and directly listed ordinary shares on Nasdaq to improve institutional visibility, eliminate ADR depositary fees, and strengthen the ability to expand the investor base.

Negatives

• Net loss significantly increased to $17.2 million in Q3 2025 from $12.9 million in Q3 2024.
• Net loss for the nine months ended September 30, 2025, dramatically increased to $40.4 million from $6.7 million in the same period of 2024.
• License and collaboration revenues decreased substantially to $16,000 in Q3 2025 from $1.2 million in Q3 2024, and to $64,000 for the nine months ended September 30, 2025, from $25.3 million in the same period of 2024.
• Research and development expenses increased to $11.1 million in Q3 2025 from $9.0 million in Q3 2024, primarily due to the initiation of Phase 2 Seabreeze STAT studies.
• General and administrative expenses increased to $6.6 million in Q3 2025 from $6.1 million in Q3 2024, due to costs incurred to support efforts to become a more U.S.-centric company.
• Cash, cash equivalents, and short-term investments decreased from $93.7 million at December 31, 2024, to $54.8 million at September 30, 2025.

Risks

• The timing and amount of actual expenses, including research and development and general and administrative expenses, may differ from expectations.
• Clinical trials may not demonstrate the safety and efficacy of product candidates or other positive results.
• The company may need expanded or additional trials to obtain regulatory approval for product candidates.
• Ability to obtain and maintain regulatory approval of product candidates is not guaranteed.
• Existing regulations and regulatory developments in the U.S., the Peoples Republic of China, Europe, and other jurisdictions could impact operations.
• The current cash and investments position may not be sufficient to support planned operations.
• Challenges in obtaining, maintaining, protecting, and enforcing intellectual property rights and proprietary technologies.
• Continued reliance on third parties to conduct additional clinical trials of product candidates and for their manufacture for preclinical studies and clinical trials.
• The degree of market acceptance of product candidates, if approved, by physicians, patients, healthcare payors, and others in the medical community is uncertain.
• Drug development and commercialization inherently involve a high degree of risk, and only a small number of research and development programs result in commercialization.
• Results in early-stage clinical trials may not be indicative of full results or results from later-stage or larger-scale clinical trials and do not ensure regulatory approval.

Future Outlook

The company expects to report topline data from its Phase 2 Seabreeze STAT asthma and COPD studies in the first half of 2026. Management is focused on patient recruitment and clinical execution for these studies. Connect Biopharma anticipates its current cash, cash equivalents, and short-term investments will be sufficient to fund operations into 2027.

Management Comments

• "Throughout 2025, we have worked diligently to position Connect for success by activating our Phase 2 Seabreeze STAT studies of rademikibart in participants experiencing acute asthma and chronic obstructive pulmonary disease (COPD) exacerbations and to further solidify our U.S. presence." Barry Quart, Pharm.D., CEO and Director.
• "As we look to the remainder of the year, we are focused on patient recruitment and clinical execution in both studies and expect to deliver topline data in the first half of 2026." Barry Quart, Pharm.D., CEO and Director.
• "We continue to work closely with Simcere in advancing rademikibart in China, making strong progress as Simcere submitted its New Drug Application (NDA) for the treatment of atopic dermatitis (AD) to Chinas National Medical Products Administration (NMPA) in July 2025 and continues to progress its Phase 3 asthma maintenance study." Barry Quart, Pharm.D., CEO and Director.

Industry Context

Connect Biopharma operates in the competitive biopharmaceutical sector, specifically targeting inflammatory diseases like atopic dermatitis, asthma, and COPD with its IL-4R antibody, rademikibart. The acceptance of Simcere's NDA for rademikibart in China for AD positions the company to potentially tap into a significant market of 70 million patients, aligning with the global trend of increasing focus on biologics for chronic inflammatory conditions. The ongoing Phase 2 studies for acute exacerbations in asthma and COPD address areas of high unmet medical need, where effective, rapid-acting treatments are highly sought after.

Stakeholder Impact

• Shareholders: Potential for future value creation from rademikibart's progress and market opportunities, but current financial losses and cash burn are a concern. Direct Nasdaq listing aims to improve institutional visibility and expand the investor base.
• Patients (AD, Asthma, COPD): Rademikibart's progress offers potential new treatment options, especially with NDA acceptance in China for AD and ongoing studies for acute exacerbations.
• Employees: Continued R&D activities and U.S.-centric focus suggest ongoing operations and potential growth opportunities.
• Simcere: Continues to advance rademikibart in Greater China, with NDA acceptance being a positive step for their commercialization efforts.

Next Steps

• Continue patient recruitment and clinical execution for Phase 2 Seabreeze STAT asthma and COPD studies.
• Report topline data from Phase 2 Seabreeze STAT asthma and COPD studies in 1H26.
• Simcere to continue progressing its Phase 3 asthma maintenance study in Greater China.
• Connect Biopharma to potentially receive remaining milestone payments and royalties from Simcere.

Key Dates

Recommendation

The company presents a mixed bag of strong clinical and regulatory progress for its lead asset, rademikibart, including NDA acceptance in China for atopic dermatitis and positive Phase 2 asthma data. These are significant long-term value drivers. However, the financial results show a substantial increase in net loss and a sharp decline in collaboration revenue, indicating a higher cash burn rate. While the cash runway into 2027 provides some stability, investors should 'hold' to monitor the progress of the ongoing Phase 2 studies, the commercialization efforts in China, and future financial performance before making further investment decisions. The stock carries inherent biopharma development risks.

Keywords

Connect Biopharma, CNTB, Rademikibart, Atopic Dermatitis, Asthma, COPD, IL-4R, Biopharmaceutical, Clinical Trials, Phase 2, NMPA, SEC Filing, Earnings, Q3 2025, Drug Development, Inflammatory Diseases